Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Women in leadership (Vice President and above) by Year
Women in leadership (Vice President and above) (%) (%)
Moderna Women in leadership (Vice President and above): 39.0% in FY2025, up 1.0 pts from a year earlier.
Latest, FY2025
39.0%
Period ended Dec 31, 2025
Change on a year earlier
+1.0 pts
38.0% in FY2024
History
7 years
Since FY2019
Sources
6
Documents cited below
Where the FY2025 figure comes from
“Among our leadership (which we define as employees at the vice president level and above), as of December 31, 2025, approximately 39% are female.”
Source: FY2025 10-K ↗
Reported in Form 10-K Item 1 (Human Capital Management) & ESG Reports.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Women in leadership (Vice President and above) (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 39.0% | +1.0 pts | FY2025 10-K ↗ |
| FY2024 | Dec 31, 2024 | 38.0% | -1.0 pts | FY2024 10-K ↗ |
| FY2023 | Dec 31, 2023 | 39.0% | -2.0 pts | FY2023 10-K ↗ |
| FY2022 | Dec 31, 2022 | 41.0% | +2.0 pts | FY2022 10-K ↗ |
| FY2021 | Dec 31, 2021 | 39.0% | +2.0 pts | FY2021 10-K ↗ |
| FY2020 | Dec 31, 2020 | 37.0% | +2.0 pts | FY2020 10-K ↗ |
| FY2019 | Dec 31, 2019 | 35.0% | – | FY2020 10-K ↗ |
Cite this data
StockData. (2026). Moderna Women in leadership (Vice President and above) (%), annual FY2019–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/hc-women-leadership-pct
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.